ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Our findings reinforce the growing awareness of the beneficial role of adiponectin-AMPK-FOXO-signaling pathway in the pathogenesis of NAFLD/NASH24, 25, suggesting that its therapeutic targeting could be exploited as a management strategy.